Brics PCG Research in its morning call recommends a "buy" on Venus Remedies with a target price of Rs 602. The current market price is Rs 355.The report states that the company has successfully completed the phase-III clinical trials of its fixed dose combination drug (FDC) comprising a latest generation cephalosporin with an amino-glycoside, developed by its R&D wing. Now, permission for the commercial launch of the drug is expected shortly.Brics PCG Research has also recommended a "buy" on Petronet LNG with a target price of Rs 90 while the current market price is Rs 55. The research firm adds that the finance and insurance for the company's Dahej expansion project are already in place.